– August 1, 2004
August 1, 2004
View Issues
-
Breast Cancer in Men: Similarities and Differences
Breast cancer is uncommon in men. In the current report, the NCI SEER database was examined to provide much needed epidemiological data on the similarities and differences of breast cancer in males and females. In general, men with breast cancer are older and present with more advanced disease. Yet, when matched for age and stage at presentation, overall survival is quite similar between men and women with this disease. -
Treatment of Advanced Non-Small-Cell Lung Cancer Patients with ECOG Performance Status 2
Single-agent chemotherapy should be the standard arm against which experimental treatments are tested in randomized trials didicated to PS 2 patients. -
Statins and Cancer Protection
In an observational study enabled by a powerful drug-dispensing record linkage system, statin use among a large number of patients treated with cardiovascular drugs, was associated with a 20% reduction in incipient cancer diagnosis over a seven year period. Although not a definitive answer, drugs in this class may have cancer protective properties, and certainly further investigation is warranted. -
HIT (Heparin-Induced Thrombocytopenia) Complications in Cancer Patients
In a retrospective review from the Royal Victoria Hospital in Montreal, among patients with heparin-induced thrombocytopenia, those who had underlying malignancy were found to have a greater risk for thrombotic events when compared to those without malignant disease. -
Prediction of Optimal vs Suboptimal Cytoreduction of Advanced-Stage Serous Ovarian Cancer with the Use of Microarrays
These data support the hypothesis that favorable survival that is associated with optimal debulking of advanced ovarian cancers is due to, at least in part, the underlying biologic characteristics of these cancers. -
Pharmacology Watch: The Importance of Publishing Negative Clinical Studies
Cognitive Effects of Estrogen Therapy; Vitamin Therapy and Restenosis; Echinacea and the Common Cold; Effects of Paxil in Children Under 18; FDA Actions. -
Clinical Briefs in Primary Care supplement